Enlivex enrolls 135 patients in phase 2b knee osteoarthritis trial

Enlivex Ltd. (ENLV) has enrolled 135 patients in its Phase 2b trial for knee osteoarthritis, with topline data expected by mid-2027. The trial evaluates Allocetra's efficacy and safety in 182 patients across the U.S., Denmark, and Poland. The FDA granted RMAT designation to the therapy in July 2026.

Original reporting
Published Oct 28, 2026, 12:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 12:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ENLV
Bullish
high confidence
Mentioned
$ENLV
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ENLVBullishMed
01

Why it matters

The enrollment update provides the first quantitative progress metric for the Phase 2b study, setting the stage for upcoming efficacy readouts.

02

Market read

The news is a primary disclosure for a micro‑cap biotech, likely to generate short‑term buying interest ahead of data release.

03

What to watch

The trial still has 47 patients to enroll and six‑month data are months away; current price may already reflect optimism.

Relevance 8/10Novelty 8/10Timing: today

Background

Enlivex is developing Allocetra, a Regenerative Medicine Advanced Therapy (RMAT) for knee osteoarthritis, a disease with no disease‑modifying treatments.

Company-level read

Ticker impact

$ENLVBullishHigh confidence
Context

Enlivex reported that 135 of the planned 182 patients have been randomized and received the first injection in its Phase 2b knee osteoarthritis trial.

Expected impact

likely upward pressure as investors price in potential positive Phase 2b results

Evidence & confidence

First‑report of patient randomization in a late‑stage trial for a biotech with no approved therapy in the space; market typically reacts favorably to progress milestones.

Market effects

May boost broader regenerative‑medicine and osteoarthritis‑therapy stocks as the trial advances.

Limited to US biotech investors; no broader regional effect.

Modest, confined to niche biotech and healthcare investors.

Counterpoint

If the trial encounters safety issues or fails to meet endpoints, the early enrollment could be a false positive for the stock.

Key entities

  • Enlivex Ltd.

    Biotech company conducting the Phase 2b trial.

  • Allocetra

    Investigational intra‑articular injection for knee osteoarthritis.

Related articles

$ENLVMed

Enlivex Reports Durable 12-Month Response With Allocetra In Knee Osteoarthritis Trial

Enlivex (ENLV) reported 12-month Phase I/IIa trial results for Allocetra, showing 79.2% of older patients with knee osteoarthritis experienced reduced pain and improved function vs. 47.6% with placebo. The therapy demonstrated a favorable safety profile. The company plans to present findings at ACR Convergence 2026 and expects Phase IIb trial data by Q2 2027. ENLV stock closed at $1.15, up 2.68%.

$ENLVMedAI 8/10

Enlivex's Allocetra Secures FDA RMAT Designation For Knee Osteoarthritis Treatment

Enlivex Ltd. (ENLV) said the FDA granted RMAT designation to its Allocetra therapy for age-related symptomatic knee osteoarthritis in older adults. The RMAT decision cites results from its completed Phase I/IIa trial showing statistically significant improvements in pain and function vs placebo, durable to six months. Enlivex is starting a Phase IIb trial enrolling 182 patients and plans an FDA Type B meeting.